October 11, 2022 Product Launch Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma Read more
October 5, 2022 Product Launch Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022 Read more
October 4, 2022 Acad, Gov/Utilities Bio/Pharma/CRO Clinical Research/Diagn. PR/Corporate Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU Read more
October 3, 2022 Uncategorized [Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023 Read more
September 19, 2022 Uncategorized European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss Read more
August 23, 2022 Clinical Research/Diagn. Life Science Tools Microscopy Product Launch Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases Read more
August 16, 2022 Acad, Gov/Utilities FDA accepts supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma Read more
August 15, 2022 Clinical Research/Diagn. Product Launch Roche launches new diagnostic test for the better understanding of immune response to SARS-CoV-2 Read more
August 12, 2022 Acad, Gov/Utilities Bio/Pharma/CRO Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older Read more
